Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
All content for Being a Life Sciences Leader is the property of Life Sciences Pennsylvania and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award. In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.&...
Being a Life Sciences Leader
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
